ALK and non-small cell lung carcinoma: For instance, identification of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), kirsten rat sarcoma viral oncogene homolog (KRAS), serine/threonine-protein kinase B-Raf (BRAF), mesenchymal-epithelial transition factor (MET), proto-oncogene tyrosine-protein kinase receptor Ret (RET), human epidermal growth factor receptor 2 (HER2), and neurotrophic receptor tyrosine kinase (NTRK) tyrosine kinase inhibitors (TKIs) have improved the outcomes for oncogene-predisposed NSCLC patients [9].